Intra-Cellular Therapies, Inc.

NasdaqGS:ITCI Voorraadrapport

Marktkapitalisatie: US$9.1b

Intra-Cellular Therapies Toekomstige groei

Future criteriumcontroles 6/6

Intra-Cellular Therapies zal naar verwachting groeien in winst en omzet met respectievelijk 68.5% en 33.5% per jaar. De winst per aandeel zal naar verwachting groeien met 68.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 37.3% zijn.

Belangrijke informatie

68.5%

Groei van de winst

68.3%

Groei van de winst per aandeel

Pharmaceuticals winstgroei23.9%
Inkomstengroei33.5%
Toekomstig rendement op eigen vermogen37.3%
Dekking van analisten

Good

Laatst bijgewerkt19 Nov 2024

Recente toekomstige groei-updates

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 10
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Recent updates

Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%

Nov 07
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

Sep 22
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

Peaking Back In On Intra-Cellular Therapies

Sep 04

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 10
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Jul 27
With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Intra-Cellular Brightens MDD Outlook With Caplyta Success

Jun 19

Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data

Apr 16

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

Apr 09
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Mar 17
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Intra-Cellular Therapies Is On Fire

Mar 11

Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'

Feb 11

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

Dec 24
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Nov 11
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Aug 07
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

May 09
Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

Apr 17
After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Jan 31
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Oct 25
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Intra-Cellular Therapies: What Lies Ahead

Sep 20

Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug

Aug 22

Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M

Aug 09

We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Jul 09
We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Intra-Cellular Therapies: A Dramatic Story

Jun 18

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Apr 03
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Intra-Cellular: Not Participating In A Bear Market

Mar 31

Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand

Mar 08

Winst- en omzetgroeiprognoses

NasdaqGS:ITCI - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20261,40439542449213
12/31/202593851786515
12/31/2024676-69-54214
9/30/2024614-86-63-62N/A
6/30/2024565-84-61-61N/A
3/31/2024514-111-99-98N/A
12/31/2023464-140-124-124N/A
9/30/2023420-155-162-161N/A
6/30/2023366-184-190-189N/A
3/31/2023311-228-248-247N/A
12/31/2022250-256-271-270N/A
9/30/2022188-298-305-304N/A
6/30/2022138-321-331-330N/A
3/31/2022103-304-296-295N/A
12/31/202184-284-260-260N/A
9/30/202171-259-255-255N/A
6/30/202156-237-239-239N/A
3/31/202138-232-227-227N/A
12/31/202023-227-230-230N/A
9/30/202010-207-196-197N/A
6/30/20203-187-163-163N/A
3/31/20201-160-144-144N/A
12/31/20190-148-129-128N/A
9/30/2019N/A-148-123-122N/A
6/30/2019N/A-155-122-121N/A
3/31/2019N/A-154-127-127N/A
12/31/2018N/A-155-119-118N/A
9/30/20180-145-115-114N/A
6/30/20180-126N/A-100N/A
3/31/20180-106N/A-91N/A
12/31/20170-98N/A-80N/A
9/30/20170-95N/A-84N/A
6/30/20170-102N/A-99N/A
3/31/20170-116N/A-88N/A
12/31/20160-116N/A-91N/A
9/30/20160-118N/A-98N/A
6/30/20160-120N/A-89N/A
3/31/20160-110N/A-106N/A
12/31/20150-105N/A-102N/A
9/30/20150-91N/A-73N/A
6/30/20150-65N/A-57N/A
3/31/20150-48N/A-32N/A
12/31/20141-31N/A-23N/A
9/30/20141-24N/A-25N/A
6/30/20142-22N/A-26N/A
3/31/20142-26N/A-27N/A
12/31/20133-27N/A-23N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat ITCI de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).

Winst versus markt: Er wordt verwacht dat ITCI de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat ITCI binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van ITCI ( 33.5% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van ITCI ( 33.5% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen ITCI zal naar verwachting over 3 jaar hoog zijn ( 37.3 %)


Ontdek groeibedrijven